Osteoarthritis - a case for personalized health care?

被引:116
作者
Karsdal, M. A. [1 ]
Christiansen, C. [1 ]
Ladel, C. [2 ]
Henriksen, K. [1 ]
Kraus, V. B. [3 ]
Bay-Jensen, A. C. [1 ]
机构
[1] Nord Biosci AS, DK-2730 Herlev, Denmark
[2] Merck KGaA, Merck Serono Res, Darmstadt, Germany
[3] Duke Univ, Sch Med, Dept Med, Div Rheumatol, Durham, NC 27706 USA
关键词
Personalized health care; Biomarkers; Treatment; Osteoarthritis; MODIFYING ANTIRHEUMATIC DRUGS; BODY-MASS INDEX; RHEUMATOID-ARTHRITIS; KNEE OSTEOARTHRITIS; EULAR RECOMMENDATIONS; BIOCHEMICAL MARKERS; BONE TURNOVER; PROINFLAMMATORY MEDIATORS; CITRULLINATED PEPTIDES; CARTILAGE DEGRADATION;
D O I
10.1016/j.joca.2013.10.018
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
For both economic and ethical reasons, identification of the optimal treatment for each individual patient is a pressing concern, not only for the patients and their physician, but also health care payers and the pharmaceutical industry. In the field of osteoarthritis (OA) this is of particular relevance, due to the heterogeneity of the disease and the very large number of affected individuals. There is a need to pair the right patients with the right therapeutic modes of action. At present, the clinical trial failures in OA may be a consequence of both bona fide treatment failures and trial failures due to clinical design deficiencies. Tools are needed for characterization and segregation of patients with OA. Key lessons may be learned from advances with another form of arthritis, namely rheumatoid arthritis (RA). Personalized health care (PHC) may be more advantageous for a number of specific indications which are characterized by costly therapy, low response rates and significant problems associated with trial and error prescription, including the risk of serious side effects. We discuss the use of diagnostic practices guiding RA treatment, which may serve as a source of key insights for diagnostic practices in OA. We discuss the emerging concept of PHC, and outline the opportunities and current successes and failures across the RA field, as the OA field collects further data to support the hypothesis. We attempt to outline a possible path forward to assist patients, physicians, payers and the pharmaceutical industry in assuring the 'right' patients are treated with the 'right drug' in OA. Finally we highlight methods for possible segregation of OA patients that would allow identification of patient subtypes, such as OA driven by inflammation that may be ideally suited for PHC and for targeted therapies. (C) 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:7 / 16
页数:10
相关论文
共 99 条
[1]   Cumulative Alendronate Dose and the Long-Term Absolute Risk of Subtrochanteric and Diaphyseal Femur Fractures: A Register-Based National Cohort Analysis [J].
Abrahamsen, Bo ;
Eiken, Pia ;
Eastell, Richard .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (12) :5258-5265
[2]   Strontium ranelate effect in postmenopausal women with different clinical levels of osteoarthritis [J].
Alexandersen, P. ;
Karsdal, M. A. ;
Byrjalsen, I. ;
Christiansen, C. .
CLIMACTERIC, 2011, 14 (02) :236-243
[3]   Increased Interleukin-1β Gene Expression in Peripheral Blood Leukocytes Is Associated With Increased Pain and Predicts Risk for Progression of Symptomatic Knee Osteoarthritis [J].
Attur, Mukundan ;
Belitskaya-Levy, Ilana ;
Oh, Cheongeun ;
Krasnokutsky, Svetlana ;
Greenberg, Jeffrey ;
Samuels, Jonathan ;
Smiles, Stephen ;
Lee, Sicy ;
Patel, Jyoti ;
Al-Mussawir, Hayf ;
McDaniel, Gary ;
Kraus, Virginia Byers ;
Abramson, Steven B. .
ARTHRITIS AND RHEUMATISM, 2011, 63 (07) :1908-1917
[4]   Radiographic severity of knee osteoarthritis is conditional on interleukin 1 receptor antagonist gene variations [J].
Attur, Mukundan ;
Wang, Hwa-Ying ;
Kraus, Virginia Byers ;
Bukowski, Jack F. ;
Aziz, Nazneen ;
Krasnokutsky, Svetlana ;
Samuels, Jonathan ;
Greenberg, Jeffrey ;
McDaniel, Gary ;
Abramson, Steven B. ;
Kornman, Kenneth S. .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (05) :856-861
[5]   A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen [J].
Barascuk, N. ;
Veidal, S. S. ;
Larsen, L. ;
Larsen, D. V. ;
Larsen, M. R. ;
Wang, J. ;
Zheng, Q. ;
Xing, R. ;
Cao, Y. ;
Rasmussen, L. M. ;
Karsdal, M. A. .
CLINICAL BIOCHEMISTRY, 2010, 43 (10-11) :899-904
[6]  
BARI ASM, 1989, BRIT J RHEUMATOL, V28, P480
[7]   Fibronectin fragments and their role in inflammatory arthritis [J].
Barilla, ML ;
Carsons, SE .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2000, 29 (04) :252-265
[8]   Hyaluronan synthesis and degradation in cartilage and bone [J].
Bastow, E. R. ;
Byers, S. ;
Golub, S. B. ;
Clarkin, C. E. ;
Pitsillides, A. A. ;
Fosang, A. J. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2008, 65 (03) :395-413
[9]   Classification of osteoarthritis biomarkers:: a proposed approach [J].
Bauer, D. C. ;
Hunter, D. J. ;
Abramson, S. B. ;
Attur, M. ;
Corr, M. ;
Felson, D. ;
Heinegard, D. ;
Jordan, J. M. ;
Kepler, T. B. ;
Lane, N. E. ;
Saxne, T. ;
Tyree, B. ;
Kraus, V. B. .
OSTEOARTHRITIS AND CARTILAGE, 2006, 14 (08) :723-727
[10]   Role of hormones in cartilage and joint metabolism: understanding an unhealthy metabolic phenotype in osteoarthritis [J].
Bay-Jensen, Anne C. ;
Slagboom, Eline ;
Chen-An, Pingping ;
Alexandersen, Peter ;
Qvist, Per ;
Christiansen, Claus ;
Meulenbelt, Ingrid ;
Karsdal, Morten A. .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2013, 20 (05) :578-586